Heartseed
Founded Year
2015Stage
Series D | AliveTotal Raised
$84.51MLast Raised
$14.33M | 4 mos agoAbout Heartseed
Heartseed focuses on the research and development of stem cell-based heart regeneration technology. It develops various treatment methods by supplementing cardiomyocytes for heart failure. The company was founded in 2015 and is based in Tokyo, Japan.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Heartseed Patents
Heartseed has filed 6 patents.
The 3 most popular patent topics include:
- Androgens and anabolic steroids
- Capacitors
- Gene expression
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/14/2015 | 2/16/2021 | Transcription factors, Stem cells, Biotechnology, Developmental biology, Cell biology | Grant |
Application Date | 7/14/2015 |
|---|---|
Grant Date | 2/16/2021 |
Title | |
Related Topics | Transcription factors, Stem cells, Biotechnology, Developmental biology, Cell biology |
Status | Grant |
Latest Heartseed News
Sep 11, 2023
TOKYO--(BUSINESS WIRE)-- #HS001--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator at the 71st Annual Meeting of the Japanese College of Cardiology (JCC) on September 9, 2023. Dr. Yuki Ichihara, Departmen
Heartseed Frequently Asked Questions (FAQ)
When was Heartseed founded?
Heartseed was founded in 2015.
Where is Heartseed's headquarters?
Heartseed's headquarters is located at 12-9 Daikyomachi, Shinjuku-ku, Tokyo.
What is Heartseed's latest funding round?
Heartseed's latest funding round is Series D.
How much did Heartseed raise?
Heartseed raised a total of $84.51M.
Who are the investors of Heartseed?
Investors of Heartseed include Sumitomo Mitsui Trust Investment, Keio Innovation Initiative, UTokyo Innovation Platform, Medical Incubator Japan, SMBC Venture Capital and 17 more.
Who are Heartseed's competitors?
Competitors of Heartseed include CUORiPS and 1 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Heartseed to Competitors
Avery Therapeutics is a company that focuses on developing tissue-engineered therapeutics to treat diseases and injuries to human muscles. Its main product, MyCardia, is being developed to address and treat heart failure. It specializes in tissue engineering therapeutics, tissue engineering, regenerative medicine, cardiology, and more. It was founded in 2016 and is based in Tucson, Arizona.
Metcela develops and commercializes therapies for heart failure and cardiac diseases. It uses specific fibroblast cells which are obtained from the patient's own heart to provides therapeutic treatments. The company serves clients operating in the healthcare sector. It was founded in 2016 and is based in Kawasaki, Japan.
Orizuru Therapeutics (OZTx) is a research and development-driven company for products including induced pluripotent stem cell (iPSC) regenerative medicine. The company aims to promote the use of cell therapy products and iPSC-related technology for the development of regenerative medical products through cell transplantation, as well as support for drug discovery research and development of regenerative medicine research infrastructure using iPSC-related technology. The company was jointly established by Takeda Pharmaceutical and Kyoto University.
BlueRock Therapeutics is a regenerative medicine company that develops induced pluripotent stem cell (iPSC) therapies to cure a range of diseases.
Vertex Pharmaceuticals (NASDAQ: VRTX) develops small molecule drugs for serious diseases. The company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
CUORiPS (TYO:4894) develops various cell therapy products. It engages in the development of allogeneic iPSC-derived cardiomyocyte sheets for the treatment of heart failure and focuses on aiding in the transplantation of the sheets for patients with severe deficiencies in their heart function. The company was founded in 2017 and is based in Tokyo, Japan.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
